18F-FDOPA PET in Neuroendocrine Tumours
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02431715|
Recruitment Status : Available
First Posted : May 1, 2015
Last Update Posted : December 30, 2016
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic. The correct treatment approach is dependent on the extent of the disease, however surgical approaches and systemic therapy can be curative.
Combined positron emission tomography/computed tomography (PET/CT) using the radiotracer 18F-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) has been shown to be a promising non-invasive technique to help localizing NETs and guide their treatment.
|Condition or disease||Intervention/treatment|
|Thyroid Cancer, Medullary Carcinoid Tumor Pheochromocytoma Paraganglioma Insulinoma Neuroblastoma||Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|
Show Detailed Description
|Study Type :||Expanded Access|
|Official Title:||[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||August 2017|
|Estimated Study Completion Date :||August 2018|
Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
All patients will have their weight and baseline vital signs recorded.
The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.
The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.
Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.
Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02431715
|Contact: Don C Wilson, MD||604-877-6000|
|Contact: Hayley Corbett|
|Canada, British Columbia|
|BC Cancer Agency|
|Vancouver, British Columbia, Canada, V5Z 4E6|
|Contact: Don C Wilson, MD 604-877-6000|
|Principal Investigator: Don C Wilson, MD|
|Sub-Investigator: Francois Benard, MD|
|Sub-Investigator: R. Petter Tonseth, MD|
|Sub-Investigator: John Powe, MD|
|Sub-Investigator: Daniel Worsley, MD|
|Sub-Investigator: Helen Nadel, MD|